Inhibikase Therapeutics Reports $13.7M Net Loss Amid Rising R&D Costs and Liquidity Improvements

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) has released its quarterly report for the period ending March 31, 2025, detailing its financial status and operational developments. Here are the key highlights:

• Income Statement Overview:
  • Total revenues for the quarter were $0, a consistent trend from the previous year.
  • Total expenses surged to $14.6 million, up from $4.8 million year-over-year, reflecting heightened investments in R&D and administrative costs.
  • The net loss for the quarter was $13.7 million, compared to a net loss of $4.6 million for the same period last year.
  • Research and development (R&D) expenses rose dramatically to $10.5 million from $2.8 million, due largely to costs associated with the acquisition of CorHepta and increased PAH program spending.
  • Selling, general, and administrative (SG&A) expenses were $5.2 million, up from $2.0 million, driven by higher legal and compliance-related costs.
  • Interest income increased significantly to $919,271 from $132,725, indicating improved returns on cash reserves.
  • Net loss per share for the quarter was $0.15, markedly better than $0.73 from the previous year.
• Balance Sheet Key Points:
  • Cash and cash equivalents grew to $73.4 million, up from $56.5 million, enhancing liquidity.
  • Total assets decreased to $94.3 million from $98.6 million.
  • The company has an accumulated deficit of $108.1 million, reflecting a continuous path of losses since inception.
  • Current liabilities rose significantly, primarily due to increases in accounts payable and contingent consideration liabilities.
• Key Developments:
  • Inhibikase is on track to initiate a Phase 2b trial for IKT-001 to treat Pulmonary Arterial Hypertension (PAH) in the latter half of 2025.
  • The stockholder meetings have resulted in a significant increase in shares reserved for the 2020 Equity Incentive Plan.
  • The acquisition of CorHepta Pharmaceuticals, completed in February 2025, is poised to add to its product pipeline despite an immediate $7.4 million write-off related to in-process research.
  • Future funding appears necessary, as the company anticipates significant future losses while it continues to develop its candidates and search for new revenue streams.
• Outlook and Considerations:
  • The management's discussions indicate a reliance on external capital to fund ongoing operations and trials amidst significant R&D expenditures.
  • Political and trade relations, especially concerning China, pose as potential risks impacting manufacturing and supply chains.
  • The urgency for additional funding could compel the company to consider further equity offerings, potentially diluting existing shareholder value.

Overall, Inhibikase Therapeutics continues to position itself for future growth with significant investments in clinical trials and product development, but faces substantial challenges in terms of profitability and capital management.